Becton Dickinson and : Dev Kurdikar Named President of BD Diabetes Care


FRANKLIN LAKES, NJ (February 8, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical device company, today announced the appointment of Dev Kurdikar, 52, as BD Diabetes Care Worldwide President effective February 10th.

In his new role, Kurdikar will be responsible for increasing global strategic, operational, and commercial performance across a portfolio of solutions that aim to minimize the stresses and complications for people with diabetes.

“Dev has spent his career in the healthcare industry in roles that span operations, finance, strategy and general management,” said Alberto Mas, executive vice president and president of the BD Medical segment. ‘This cross-functional experience, coupled with a practical and authentic leadership style, has enabled him to build high-performing teams and a successful culture. His bold and strategic approach and proven ability to iterate, try new things, and embrace change make him well suited to lead the diabetes care business.

Most recently, Kurdikar was CEO and President of Cardiac Science, a global manufacturer of automated external defibrillators (AEDs). Previously, he was general manager of the men’s health business for American Medical Systems (AMS) and held positions of increasing responsibility and leadership at Baxter including vice president of infusion systems business in the United States and vice president of marketing / strategy for company-wide commercial initiatives.

Kurdikar earned an MBA majoring in Finance & Strategy from Washington University, Missouri, and a Ph.D. in Chemical Engineering from Purdue University in Indiana. He is currently a member of the LMG Holdings Board of Directors.

About BD

BD is one of the world’s largest medical device companies, driving the world of health by improving medical discovery, diagnostics, and care delivery. The company supports the heroes at the frontline of the healthcare industry by developing innovative technologies, services, and solutions that help advance both clinical therapy for patients and the clinical process for healthcare providers. BD and its 70,000 employees are passionate and committed to improving the safety and efficiency of the clinician’s nursing process, enabling laboratory scientists to accurately identify disease, and improving the skills of researchers to develop the next generation of diagnostics and therapeutics. BD is present in virtually every country and works with organizations around the world to address some of the toughest global health problems. By working closely with customers, BD can help improve outcomes, reduce costs, increase efficiency, improve safety, and expand access to health care. For more information on BD, please visit or LinkedIn at and Twitter @BDandCo.


Troy Kirkpatrick
BD Public Relations

Kristen M. Stewart, CFA
BD Investor Relations

Disclaimer of liability

BD – Becton, Dickinson and Company published this content on February 08, 2021 and is solely responsible for the information contained therein. Distributed by the public, unedited and unchanged, on February 09, 2021 20:50:01 UTC.